Mosquirix_summary_slide_figshare.JPG (222.2 kB)

RTS,S/AS01 malaria vaccine (Mosquirix®): a profile of its use

online resource

posted on 2022-09-06, 14:18 authored by Yahiya Y. Syed

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability not applicable

Additional information about this Adis Drug Review can be found here

Abstract

RTS,S/AS01 (Mosquirix®), the first malaria vaccine, is indicated for the active immunisation of children against malaria caused Plasmodium falciparum. In a phase 3 trial, RTS,S/AS01 showed efficacy against P. falciparum malaria, with an acceptable safety and tolerability profile in children aged 6 weeks to 17 months. The efficacy was greater in children aged 5–17 months than in infants aged 6–12 weeks. In another phase 3 trial, RTS,S/AS01 was noninferior to chemoprevention in preventing seasonal malaria in children. WHO recommends a 4-dose schedule of RTS,S/AS01 for the prevention of P. falciparum malaria in children from 5 months of age living in African regions with moderate to high malaria transmission, with an optional 5-dose schedule for seasonal malaria. Preliminary results from large pilot studies in Africa show that RTS,S/AS01 substantially reduces malaria episodes, increases equity in access to malaria prevention, is highly cost effective and can be delivered through the routine national immunization programmes.